35603567|t|Identification of novel natural inhibitors targeting AKT Serine/Threonine Kinase 1 (AKT1) by computational study.
35603567|a|Despite great progress, the current cancer treatments often have obvious toxicity and side effects. and a poor prognosis (some patients). One of the reasons for the poor prognosis is that certain enzymes prevent anticancer drugs from killing tumor cells. AKT1 is involved in regulating PI3K/AKT/mTOR, a tumor-generating pathway. Ipatasertib, a highly selective inhibitor of AKT1, is widely used in the treatment of tumors. In this study, many structural and biochemical methodswere used to find better AKT1(Threonine Kinase 1) inhibitors, which laid a foundation for the further development of AKT1 inhibitors and provided new drugs for the treatment of tumors. ZINC15 database and Discovery Studio 4.5, a computer-aided drug screening software with many modules (LibDock for virtual screening, ADME (Absorption, Distribution, Metabolism, Excretion) and TOPKAT (toxicity prediction module) for the toxicity and properties analysis, and MD simulation for stability prediction), were employed. CCK8 assay, ELISA assay genicity and higher tolerance to cytochrome P4502D6. MD simulations indicated they could bind with AKT1 stably in the natural environment. The cell experiment and specific assay for AKT1 inhibition showed they could inhibit the proliferation and AKT1 expression of MG63 cells (Osteosarcoma cells). Moreover, these novel compounds with structural modifications can be potential contributors that lead to further rational drug design for targeting AKT1.AbbreviationAKT1, AKT Serine/Threonine Kinase 1; ADME, absorption, distribution, metabolism, excretion; TOPKAT, toxicity prediction by Computer assisted technology; CCK8, Cell Counting Kit 8; ELISA, Enzyme-linked immunosorbent assay; CYP2D6, cytochrome P4502D6 inhibition; GBM, Glioblastoma; AGC kinase, protein kinase A, G, and C families (PKA, PKC, PKG); PKB, protein kinase B; PAM pathway, PI3K/AKT/mTOR pathway; OS, overall survival; PFS, progression-free survival; LD50, lethal dose half in rats; LOAEL, lowest observed adverse effect level; NPT, normal pressure and temperature; PME, particle mesh Ewald; LINCS, linear constraint solver; RMSD, root-mean-square deviation; BBB, blood-brain barrier; DS, Discovery Studio; DTP, Developmental toxicity potential; PPB, Plasma protein binding; MTD, Maximum Tolerated Dosage; AB, Aerobic Biodegradability; NTP, US. National Toxicology Program; DTP, developmental toxicity potential.
35603567	53	82	AKT Serine/Threonine Kinase 1	Gene	207
35603567	84	88	AKT1	Gene	207
35603567	150	156	cancer	Disease	MESH:D009369
35603567	187	195	toxicity	Disease	MESH:D064420
35603567	241	249	patients	Species	9606
35603567	356	361	tumor	Disease	MESH:D009369
35603567	369	373	AKT1	Gene	207
35603567	405	408	AKT	Gene	207
35603567	409	413	mTOR	Gene	2475
35603567	417	422	tumor	Disease	MESH:D009369
35603567	443	454	Ipatasertib	Chemical	MESH:C583616
35603567	488	492	AKT1	Gene	207
35603567	529	535	tumors	Disease	MESH:D009369
35603567	616	620	AKT1	Gene	207
35603567	708	712	AKT1	Gene	207
35603567	768	774	tumors	Disease	MESH:D009369
35603567	976	984	toxicity	Disease	MESH:D064420
35603567	1012	1020	toxicity	Disease	MESH:D064420
35603567	1163	1181	cytochrome P4502D6	Gene	1565
35603567	1229	1233	AKT1	Gene	207
35603567	1312	1316	AKT1	Gene	207
35603567	1376	1380	AKT1	Gene	207
35603567	1395	1399	MG63	CellLine	CVCL:0426
35603567	1407	1419	Osteosarcoma	Disease	MESH:D012516
35603567	1576	1597	AKT1.AbbreviationAKT1	Gene	207
35603567	1599	1628	AKT Serine/Threonine Kinase 1	Gene	207
35603567	1693	1701	toxicity	Disease	MESH:D064420
35603567	1815	1821	CYP2D6	Gene	1565
35603567	1823	1841	cytochrome P4502D6	Gene	1565
35603567	1854	1857	GBM	Disease	MESH:D005910
35603567	1859	1871	Glioblastoma	Disease	MESH:D005909
35603567	1927	1930	PKC	Gene	112476
35603567	1932	1935	PKG	Gene	5592
35603567	1938	1941	PKB	Gene	207
35603567	1943	1959	protein kinase B	Gene	2185
35603567	1979	1982	AKT	Gene	207
35603567	1983	1987	mTOR	Gene	2475
35603567	2077	2081	rats	Species	10116
35603567	2326	2334	toxicity	Disease	MESH:D064420
35603567	2454	2464	Toxicology	Disease	
35603567	2493	2501	toxicity	Disease	MESH:D064420
35603567	Association	MESH:D009369	207
35603567	Association	207	2475
35603567	Association	MESH:D005909	207
35603567	Association	MESH:D009369	2475
35603567	Negative_Correlation	MESH:C583616	MESH:D009369
35603567	Association	112476	207
35603567	Association	MESH:D005910	207
35603567	Association	MESH:D064420	207
35603567	Association	207	2185
35603567	Association	1565	207
35603567	Association	MESH:D012516	207
35603567	Association	207	5592
35603567	Negative_Correlation	MESH:C583616	207

